iTherX (United States)

Recent papers from iTherX (United States)

1. Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantationLiver Transplantation · 2015
2. Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agentsHepatology · 2014
3. Safety and Antiviral Activity of the HCV Entry Inhibitor ITX5061 in Treatment-Naive HCV-Infected Adults: A Randomized, Double-Blind, Phase 1b StudyThe Journal of Infectious Diseases · 2013
4. Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus AntiviralsThe Journal of Infectious Diseases · 2012
5. Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell TransmissionJournal of Virology · 2010
6. Targeting HCV Entry For Development of TherapeuticsViruses · 2010
7. Increased HDL Cholesterol and ApoA-I in Humans and Mice Treated With a Novel SR-BI InhibitorArteriosclerosis Thrombosis and Vascular Biology · 2009
8. A method for detecting and preventing negative RNA interference in preparation of lentiviral vectors for siRNA deliveryRNA · 2009
9. Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination TherapyPLoS ONE · 2008
10. Oncolytic virotherapy as a personalized cancer vaccineInternational Journal of Cancer · 2008
11. Generation of shRNA Pool Library: A Revision of the Biological Technique from the Viewpoint of ChemistryChemBioChem · 2008